Incidence of hypersensitivity skin reactions in patients on full-dose low-molecular-weight heparins during pregnancy

Netherlands Journal of Medicine

Volumn 71, Issue 10, 2014, Pages 518-522

  Schultinge, L ^a   Knol, H M ^a   Kluin Nelemans, H C ^a   Erwich, J J H M ^a   Meijer, K ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anticoagulation; Hypersensitivity skin reactions; LMWH; Pregnancy; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; DALTEPARIN; DANAPAROID; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN;

ADULT; ANTICOAGULATION; APPLICATION SITE PRURITUS; ARTICLE; COHORT ANALYSIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; FEMALE; FETUS WASTAGE; HUMAN; PREGNANCY; PREGNANCY OUTCOME; RASH; RECURRENT DISEASE; SKIN ALLERGY; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84891871897     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bank I, Libourel EJ, Middeldorp S, Van Der Meer J, Buller HR. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost. 2003;1:859-61.
2. Mehndiratta S, Suneja A, Gupta B, Bhatt S. Fetotoxicity of warfarin anticoagulation. Arch Gynecol Obstet. 2010;282:335-7.
3. Wainwright H, Beighton P. Warfarin embryopathy: fetal manifestations. Virchows Arch. 2010;457:735-9.
4. Wesseling J, Van Driel D, Smrkovsky M, et al. Neurological outcome in school-age children after in utero exposure to coumarins. Early Hum Dev. 2001;63:83-95.
5. Knol HM, Schultinge L, Erwich JJ, Meijer K. Fondaparinux as an alternative anticoagulant therapy during pregnancy. J Thromb Haemost. 2010;8:1876-9.
6. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost. 2006;96:611-7.
7. Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causes of heparin-induced skin lesions. CMAJ. 2009;181:477-81.
8. Wutschert R, Piletta P, Bounameaux H. Adverse skin reactions to low molecular weight heparins: frequency, management and prevention. Drug Saf. 1999;20:515-25.
9. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecularweight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668-72.
10. Santoro R, Iannaccaro P, Prejan S, Muleo G. Efficacy and safety of the long-term administration of low-molecular-weight heparins in pregnancy. Blood Coag Fibrinol. 2009;20:240-3.
11. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106:401-7.
12. Schindewolf M, Lindhoff-Last E, Ludwig RJ, Boehncke WH. Heparin-induced skin lesions. Lancet. 2012;380:1867-79.
13. Kaandorp SP, Goddijn M, van der Post JA, et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362:1586-96.
14. Schindewolf M, Gobst C, Kroll H, et al. High incidence of heparin-induced allergic delayed-type hypersensitivity reactions in pregnancy. J Allergy Clin Immunol. 2013;132:131-9.
15. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004;350:1914-5.